OpGen (OPGN) Hits New 1-Year Low at $1.02

OpGen Inc (NASDAQ:OPGN) hit a new 52-week low during trading on Thursday . The company traded as low as $1.02 and last traded at $1.05, with a volume of 623 shares. The stock had previously closed at $1.09.

OPGN has been the subject of a number of recent research reports. HC Wainwright set a $6.00 price target on shares of OpGen and gave the stock a “buy” rating in a report on Wednesday. Zacks Investment Research downgraded shares of OpGen from a “buy” rating to a “hold” rating in a report on Wednesday, November 7th.

The firm has a market capitalization of $9.08 million, a P/E ratio of -0.11 and a beta of 1.92. The company has a current ratio of 1.56, a quick ratio of 1.43 and a debt-to-equity ratio of 0.28.

OpGen (NASDAQ:OPGN) last issued its quarterly earnings results on Tuesday, November 13th. The medical research company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.02. The business had revenue of $0.55 million during the quarter, compared to the consensus estimate of $0.56 million. OpGen had a negative net margin of 395.63% and a negative return on equity of 238.35%. Analysts expect that OpGen Inc will post -2.19 EPS for the current fiscal year.

A hedge fund recently bought a new stake in OpGen stock. B. Riley Financial Inc. purchased a new position in shares of OpGen Inc (NASDAQ:OPGN) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 138,000 shares of the medical research company’s stock, valued at approximately $246,000. B. Riley Financial Inc. owned approximately 2.22% of OpGen at the end of the most recent reporting period. Hedge funds and other institutional investors own 4.08% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.com-unik.info/2018/12/08/opgen-opgn-hits-new-1-year-low-at-1-02.html.


OpGen, Inc, a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide. The company utilizes molecular diagnostics and bioinformatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms.

Featured Article: What is a Leveraged Buyout (LBO)?

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit